IDEXX Laboratories, Inc.

NASDAQ:IDXX

Medical - Diagnostics & Research

Healthcare
$698.47 +2.26%

+$12.33 today

Market cap
$55.03B
Beta
1.54
P/E (TTM)
40.8
EPS (TTM)
$13.67
52W Low $506.91High $769.98

Volume 0.37M

Average 0.58M

IDXX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

IDEXX Laboratories, Inc.NASDAQ: IDXX

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 62.9%

Gross margin was 62.9% in Q3 FY2026, up 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 62.7%, up 1.0 pp year over year. Over 3 fiscal years it widened by 2.3 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
62.9%-1.1 pp QoQ
Last fiscal yearDec 2025
61.8%+0.8 pp YoY
LTMSep 2026
62.7%+1.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.1 pp——
1 year+0.8 pp——
3 years+2.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
61.8%
Year-over-year change
+0.8pp

Gross Margin vs competitors

How IDXX compares with its peers on the latest reported figures

  • IDXX's LTM Sep 2026 gross margin of 62.7% is the 3rd highest of the 5 companies compared; the peer median is 62.2%.
  • Its year-over-year change of +1.0 pp is the 3rd highest of 5, against a peer median of +3.6 pp.
  • Over three fiscal years its change of +2.3 pp compares with a peer median of +0.1 pp.
IDXX Competitors Peer median
Gross Margin for IDXX and competitors
Company Period LTM level YoY 3-year change
MRKMerck & Co., Inc.LTM Jun 202675.4% -0.1 pp+1.3 pp
ZTSZoetis Inc.LTM Jun 202670.9% +0.8 pp+2.7 pp
IDXXIDEXX Laboratories, Inc.LTM Sep 202662.7% +1.0 pp+2.3 pp
ELANElanco Animal Health IncorporatedLTM Sep 202653.5% +7.1 pp-1.2 pp
NEOGNeogen CorporationLTM Aug 202647.4% +6.3 pp-2.4 pp
Peer median (excluding IDXX) 62.2%+3.6 pp+0.1 pp

Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.22B3.37B3.66B3.9B4.3B
Cost of Revenue1.33B1.36B1.47B1.52B1.64B
Gross Profit1.89B2B2.19B2.38B2.66B
Gross Margin58.8%59.5%59.8%61.0%61.8%
Research & Development161.01M254.82M190.95M219.79M251.21M
Selling, General & Admin796.4M850.75M901.89M1.03B1.05B
Operating Expenses957.4M1.11B1.09B1.25B1.3B
Depreciation & Amortization104.6M111.9M114.91M129.94M145.18M
EBITDA1.04B1.01B1.22B1.28B1.51B
EBITDA Margin32.3%30.1%33.3%32.7%35.0%
Operating Income932.03M898.77M1.1B1.13B1.36B
Operating Margin29.0%26.7%30.0%29.0%31.6%
Interest Income434K1.07M5.63M12.7M2.42M
Interest Expense29.81M39.86M41.58M31.21M38.27M
Other Income / Expenses(29.37M)(38.79M)(35.95M)(18.51M)(35.84M)
Income Before Tax902.65M859.97M1.06B1.11B1.32B
Pre-Tax Margin28.1%25.5%29.0%28.5%30.8%
Income Tax Expense157.81M180.88M216.13M221.96M264.73M
Net Income744.85M679.09M845.04M887.87M1.06B
Net Margin23.2%20.2%23.1%22.8%24.6%
EPS (Basic)8.748.1210.1710.7713.17
EPS (Diluted)8.608.0310.0610.6713.08
Weighted Avg Shares85.2M83.62M83.07M82.47M80.1M
Weighted Avg Shares (Diluted)86.57M84.6M83.98M83.25M80.68M

IDEXX Laboratories, Inc.

NASDAQ:IDXX

Intrinsic Alpha fair value

Locked

Current Price

$698.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.